Invima warned about a counterfeit batch of Noxpirin that would be circulating in the country and that represents a health risk.
Invima issued a health alert after detecting the circulation of a counterfeit batch of Noxpirin Plus capsules.
The National Institute for Food and Drug Surveillance (Invima) presented a health alert after detecting the illegal circulation and marketing in the country of a counterfeit product identified as NOXPIRIN PLUS CAPSULE Lot 15890724expiration date 07-2026.
More news: Ministry of Mobility clarifies doubts about changes in the peak and plate from 2026
According to the entity, this product represents a risk to the health of Colombians.
According to the Siegfried SAS Laboratory, holder of the health registration of the medicine, the counterfeit product irregularly uses its brand, its batch and its expiration date.
“After receiving notification from the laboratory, Invima confirmed that the batch in question corresponds to a “twin batch” that was not produced by the company and presents multiple differences compared to the original medicine,” he explained.
William Saza, director of Medicines and Biological Products at Invima, called on Colombians to verify the product carefully.
You may be interested in: They capture the alleged urban leader of the dissidents in Palmira: he was going to install parades
“The counterfeiting of a medicine not only deceives the consumer, but also puts their health at risk. We invite citizens to always verify the health record and to refrain from purchasing products whose authenticity raises doubts,” he stated.
According to Invima, NOXPIRIN PLUS CÁPSULA has the current health registration INVIMA 2015M-0004030-R1, under the Make and Sell modality. However, the manufacturing laboratory showed that the counterfeit product has notable modifications, including:
- Changes in the color and shine of the packaging.
- Variations in layout and graphic design.
- Alterations in typography and size of texts.
- Coding different from that registered on the authentic product.
- Differences in the art of primary packaging (foil), including color, typography and content.
- Changes in the physical characteristics of the capsule.
According to Decree 677 of 1995this product is classified as counterfeit and fraudulent, since its real composition, manufacturing, transportation and storage conditions are unknown, which voids any guarantee of quality, safety or effectiveness.
Invima called on consumers to: Do not acquire or consume the counterfeit product identified with lot 15890724 FV 07-2026. Avoid purchasing medications without health registration, especially those offered on the internet, social networks or informal messaging.
Source: Integrated Information System
